Brookdale

Analysts at UBS turned bearish on HCP, Inc. (NYSE: HCP) as the Street is "underappreciating" negative headwinds that will impact the stock moving forward. The firm's Nick Yulico downgrades HCP's stock rating from Neutral to Sell with a price target lowered from $30 to $25. Of particular concern is...